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                         I. INTRODUCTION 
                   Over the past 30 years, as the expense and complications involved in 
marketing new drug entities have increased, with concomitant recognition of the 
therapeutic advantages of controlled drug delivery, greater attention has been 
focused on development of sustained or controlled release drug delivery systems. 
The attractiveness of these dosage forms is due to awareness to toxicity and 
ineffectiveness of drugs when administered or applied by conventional method in 
the form of tablets, capsules, injectables, ointments etc. Usually conventional dosage 
form produce wide ranging fluctuation in drug concentration in the blood stream and 
tissues with consequent undesirable toxicity and poor efficiency. This factors as well 
as factors such as repetitive dosing and unpredictable absorption led to the concept 
of controlled drug delivery systems.  
                  The goal in designing sustained or controlled delivery systems is to 
reduce the frequency of the dosing or to increase effectiveness of the drug by 
localization at the site of action, reducing the dose required or providing uniform 
drug delivery
1
. So, controlled release dosage form is a dosage form that release one 
or more drugs continuously in a predetermined pattern for a fixed period of time, 
either systemically or to a specified target organ. Controlled release dosage forms 
provide a better control of plasma drug levels, less dosage frequency, less side 
effect, increased efficacy and constant delivery. 
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1.1. Oral drug delivery:
 2, 3, 4, 5 
                   This is the most widely utilized route of administration among all the 
routes that have been explored for systemic delivery of drugs via different dosage 
form. Oral route is considered most natural, uncomplicated, convenient and safe due 
to its ease of administration, patient acceptance and cost effective manufacturing 
process. 
                  For the past decades, there has been enhanced demand for patient 
complaint dosage forms. As a result the demand for the technologies has been 
increased 3 fold annually. Since the development cost of new chemical entity is very 
high, the pharmaceutical companies are focusing on the development of new drug 
delivery systems for existing drug with an improved efficacy and bioavailability 
together with reduced dosing frequency to minimize the side effects. 
                   Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
and development of new drug entities, pharmaceutical formulations, mainly because 
of patient acceptance and convenience in administration.  
                   Oral route of drug administration have wide acceptance up to 50-60% of 
total dosage forms. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self medication, pain avoidance and most 
importantly patient compliance. The most popular solid dosage forms are tablets and 
capsules. But the important drawback of these dosage forms are difficulty to 
swallow. 
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1.2. Modified Drug Delivery Systems
 8
  
                   Dosage forms can be designed to modify the release of the drug over a 
given time or after the dosage form reaches the required location. Drug release 
occurs only after some time of the administration or for a prolonged period of time 
or to a specific target in the body. Modifications in drug release are often desirable 
to increase the stability, safety and efficacy of the drug, to improve the therapeutic 
outcome of the drug treatment or to increase patient compliance and convenience of 
administration. 
1.3. Classification
7
: 
                    Modified Release dosage form may be classified as 
 Extended Release 
 Sustained Release 
 Controlled Release 
 Delayed Release 
 Site Specific Targeting 
 Receptor targeting. 
 
1.3.1. Extended Release (ER):  
                    This type of oral Drug delivery system allows the drug to be released 
over prolonged time periods. By extending the release profile of a drug, the 
frequency of dosing can be reduced.  Extended release can be achieved using 
sustained or controlled-release dosage forms. 
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 1.3.2. Sustained Release (SR):  
                    This term Extended or Sustained is constantly used to describe a 
pharmaceutical dosage form formulated to retard the release of the therapeutic agent 
such that its appearance in the systemic circulation is delayed and prolonged and its 
plasma profile is Sustain in duration. The onset of its pharmacological action is often 
delayed, and the duration of its therapeutic effect is sustained. In orally administered 
dosage forms, this duration is in hours and critically depends on the residence time 
of the dosage form in GI tract, where as in the case of injectables this period may 
vary from days to months. 
1.3.2a. Advantages of ER/SR Dosage Forms
 11
: 
 
 Improved patient compliance due to reduced frequency of drug 
administration. 
 The blood level oscillations characteristic of conventional dosage forms is 
reduced. 
 A less obvious advantage that the total amount of drug administered can be 
reduced, thus maximizing availability with minimum dose. 
 Better control of drug absorption can be attained, since the high blood level 
peaks that may be observed after administration of a dose of high availability 
drug can be reduced by formulation in an extended action form. 
 The safety margin of high potency drugs can be increased, and the incidence 
of both local and systemic adverse side effects can be reduced in sensitive 
patients. 
 Reliable therapy. 
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1.3.2b. Disadvantages: 
11 
 Administration of Extended Release(ER) medication does not permit the 
prompt termination of therapy. 
 Less flexibility in adjusting dosage regimen. 
 Sustained release forms are designed for normal population, i.e., on the basis 
of biological half-lives. Consequently, disease states that alter drug 
disposition, significant patient variation, and so forth are not accommodated. 
 Economic factors.   
1.3.2c. Drug candidates that is suitable for ER/SR Dosage Forms:
 
 Should be effectively absorbed in small intestine. 
 Biological half life should lie within 1-12hours. 
 Dosage that is not titrated according to individual. 
 Small doses(<1g)  
     
Fig:1.1 Plasma Dug Concentration Profiles for Conventional Tablet 
Formulation. 
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a. Extended/Sustained Release Formulation and a Zero Order Controlled 
Release Formulation.        
                    ER/SR system generally don’t attain zero order type release and usually 
try to mimic zero order release by providing drug in a slow first order. Repeat action 
tablet are an alternative method of sustained release in which multiple doses of drug 
are contained within a dosage form and each dose is released at a periodic interval. 
Delayed release system, in contrast, may not be sustaining, since often the function 
of these dosage forms is to maintain the drug in the dosage for some time before its 
release, Eg: Enteric coated tablet or capsules.  
                    The ideal way of providing an exact amount of drug at the site of action 
for a precise time period is usually approximated by most systems. This 
approximation is achieved by creating a constant concentration in the body organ 
over an extended time in other words, the amount of drug entering the system is 
equivalent to the amount of drug removed from the system. All forms of metabolism 
and excretion are included in the removal process urinary excretion, enterohepatic 
recycling, sweat, fecal and so on. Since, for most of the drugs these elimination 
processes are first order, it can be said that a certain blood level, the drug will have a 
specific rate of elimination. The idea is to deliver drug at this exact rate for an 
extended period. This is represented mathematically as following, 
                             Rate in = Rate out = kelim × Cd × Vd 
Where Cd is the desired drug level,  
           Vd is the volume of distribution and 
          kelim is the rate constant of drug elimination from the body. 
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1.3.3. PHYSICOCHEMICAL FACTORS INFLUENCING ORAL 
EXTENDED-RELEASE DOSAGE FORM DESIGN 
13, 14
 
a. Dose size: 
                    For orally administered systems, there is an upper limit to the bulk size 
of the dose to be administered. In general, a single dose of 0.5- 1.0g is considered 
maximal for a conventional dosage form. This also holds for sustained release 
dosage form. Compounds that require large dosing size can sometimes be given in 
multiple amounts or formulated into liquid systems. Another consideration is the 
margin of safety involved in administration of large amount of a drug with a narrow 
therapeutic range. 
b. Ionization, pka and aqueous solubility:
 
 
                    Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the 
relationship between the pka of the compound and the absorptive environment. 
Presenting the drug in an unchanged form is advantageous for drug permeation. 
Unfortunately, the situation is made more complex by the fact that the drug’s 
aqueous solubility will generally be decreased by conversion to unchanged form. 
Delivery systems that are dependent on diffusion or dissolution will likewise be 
dependent on the solubility of the drug in aqueous media. These dosage forms must 
function in an environment of changing pH, the stomach being acidic and the small 
intestine more neutral, the effect of pH on the release process must be defined. 
                    Compounds with very low solubility (<0.01mg/ml) are inherently 
sustained, since their release over the time course of a dosage form in the Gastro 
Intestinal tract will be limited by dissolution of the drug. So it is obvious that the 
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solubility of the compound will be poor choices for slightly soluble drugs, since the 
driving force for diffusion, which is the drug’s concentration in solution, will be 
low. 
c. Partition Coefficient:
  
                     When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect in another area of the body. It 
is common to consider that these membranes are lipidic; therefore the partition 
coefficient of oil-soluble drugs becomes important in determining the effectiveness 
of membrane barrier penetration. Compounds which are lipophilic in nature having 
high partition coefficient are poorly aqueous soluble and it retain in the lipophilic 
tissue for the longer time. In case of compounds with very low partition coefficient, 
it is very difficult for them to penetrate the membrane, resulting in poor 
bioavailability. Furthermore, partitioning effects apply equally to diffusion through 
polymer membranes. The choice of diffusion-limiting membranes must largely 
depend on the partitioning characteristics of the drug. 
d. Stability:
 
                     Orally administered drugs can be subjected to both acid-base 
hydrolysis and enzymatic   degradation. Degradation will proceed at a reduced rate 
for drugs in solid state. For the dosage form that are unstable in stomach, systems 
that prolong delivery over entire course of transit in the GI tract are beneficial. This 
is also true for systems that delay release until the dosage form reaches the small 
intestine. Compounds that are unstable in small intestine may demonstrate decreased 
bioavailability when administered from a sustaining dosage form. This is because 
more drugs are delivered in the small intestine and, hence, is subject to degradation.  
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1.3.4. BIOLOGICAL FACTORS INFLUENCING ORAL EXTENDED-
RELEASE DOSAGE FORM DESIGN
 13, 14 
 Biological half life. 
 Absorption. 
 Metabolism. 
a. Biological half life: 
                     The usual goal of an oral Extended Release product is to maintain 
therapeutic blood levels over an extended period of time. To achieve this, drug must 
enter the circulation at approximately the same rate at which it is eliminated. The 
elimination rate is quantitatively described by the half-life (t1/2). Each drug has its 
own characteristic elimination rate, which is the sum of all elimination processes, 
including metabolism, urinary excretion and all over processes that permanently 
remove drug from the blood stream. Therapeutic compounds with short half-life are 
generally are excellent candidate for SR formulation, as this can reduce dosing 
frequency. In general, drugs with half-lives shorter than 2 hours such as furosemide 
or levodopa are poor candidates for SR preparation. Compounds with long half-
lives, more than 10 hours are also generally not used in sustaining form, since their 
effect is already sustained. Digoxin and phenytoin are the examples. 
b. Absorption: 
                     Since the purpose of forming a SR/ER product is to place control on 
the delivery system, it is necessary that the rate of release is much slower than the 
rate of absorption. If we assume that the transit time of most drugs in the absorptive 
areas of the GI tract is about 8-12 hours, the maximum half-life for absorption 
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should be approximately 3-4 hours otherwise, the device will pass out of the 
potential absorptive regions before drug release is complete. This corresponds to a 
minimum apparent absorption rate constant of 0.17-0.23h-1 to give 80-95% over 
this time period.  
                     Hence, it assumes that the absorption of the drug should occur at a 
relatively uniform rate over the entire length of small intestine. For many 
compounds this is not true. If a drug is absorbed by active transport or transport is 
limited to a specific region of intestine, ER preparation may be disadvantageous to 
absorption. One method to provide sustaining mechanisms of delivery for 
compounds is to maintain them within the stomach. This allows slow release of the 
drug, which then travels to the absorptive site. These methods have been developed 
as a consequence of the observation that co-administration results in sustaining 
effect. One such attempt is to formulate low density pellet or capsule. Another 
approach is that of bioadhesive materials. 
c. Metabolism: 
                     Drugs those are significantly metabolized before absorption, either in 
the lumen or the tissue of the intestine, can show decreased bioavailability from 
slower-releasing dosage form. Hence criteria for the drug to be used for formulating 
Extended-Release dosage form is, 
 Drug should have low half-life(<5 hrs) 
 Drug should be freely soluble in water. 
 Drug should have larger therapeutic window. 
 Drug should be absorbed throughout the GIT. 
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                     Even a drug that is poorly water soluble can be formulated in SR/ER 
dosage form. For the same, the solubility of the drug should be increased by the 
suitable system and later on that is formulated in the SR dosage form. But during 
this the crystallization of the drug, that is taking place as the drug is entering in the 
systemic circulation, should be prevented. 
1.3.5. Controlled Release Dosage:  
                     Controlled Release dosage form is generally accomplished by 
attempting to obtain “zero- order” release from the dosage form which is 
independent of the amount of drug in the delivery system (i.e., a constant release 
rate). Sustained Release systems generally do not attain this type of release and 
usually try to mimic zero order release by providing drug in a slow first order 
fashion (i.e., concentration dependent). 
                     The controlled release systems for oral use are mostly solids and based 
on dissolution, diffusion or a combination of both mechanisms in the control of 
release rate of drug. Depending upon the manner of drug release, these systems are 
classified as follows: 
a. Continuous release systems
 13 
                     These systems release the drug for a prolonged period of time along the 
entire length of gastrointestinal tract with normal transit of the dosage form. 
The various systems under this category are as follows: 
1. Dissolution controlled release systems 
2. Diffusion controlled release systems 
3. Dissolution and diffusion controlled release systems 
4. Ion exchange resin- drug complexes 
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5. pH dependent formulation 
6. Osmotic pressure controlled systems 
b. Delayed transit and continuous release systems
13 
                     These systems are designed to prolong their residence in the GI tract 
along with their release. Often the dosage form is fabricated to retain in the stomach 
and hence the drug present therein should be stable in gastric pH. Systems included 
in this category are mucoadhesive systems and size based systems. 
1.3.6. Delayed Release 
15, 16
 
                     A Delayed Release dosage form is designed to release the drug at a 
time other than promptly after administration. Dosage forms can be designed to 
modify the release of the drug over a given time or after the dosage form reaches the 
required location. 
                     Delayed Release oral dosage forms can control where the drug is to be 
released, e.g. when the dosage form reaches the small intestine (Enteric-coated 
dosage forms) or the colon (colon-specific dosage forms).   
                     Delayed Release systems release a bolus of the drug after a 
predetermined time in a predetermined location, i.e. they do not release the drug 
immediately after ingestion, for example Enteric-coated tablets and pulsatile-release 
capsules.
  
                     Delayed Release dosage forms are designed to provide spatial 
placement or temporal targeted delivery of a drug to the distal human gut. Spatial 
placement relates to targeting a drug to a specific organ or tissue, while temporal 
delivery refers to desired rate of drug release to target tissue over a specified period 
of time. 
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                     The correct selection and balance of excipients and processes in solid 
dosage formulations are designed either for improving the micromeritic or 
macromeritic properties of materials during manufacture and/or for providing a 
desired drug delivery system. The most commonly used pharmaceutical sustained 
release solid oral dosage forms today include Tablets, Capsules, Granules and 
Pellets. 
Site specific targeting: 
                     These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is adjacent to or in the diseased organ or 
tissue. 
Receptor targeting: 
                     These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is the particular receptor for a drug within 
an organ or tissue. 
                       Site specific targeting and receptor targeting systems satisfy the 
spatial aspect of drug delivery and are also considered to be controlled drug delivery 
systems. 
 
1.4. ALZHEIMER'S DISEASE
 23, 24, 25
 
                     Alzheimer's disease also known in medical literature as Alzheimer 
disease, is the most common form of dementia. There is no cure for the disease, 
which worsens as it progresses, and eventually leads to death. As the disease 
advances, symptoms can include confusion, irritability and aggression, mood 
swings, trouble with language, and long-term memory loss. As the sufferer declines 
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they often withdraw from family and society. Gradually, body functions are lost, 
ultimately leading to death. 
                     The cause and progression of Alzheimer's disease are not well 
understood. Research indicates that the disease is associated with 
plaques and tangles in the brain. Current treatments only help with the symptoms of 
the disease. There are no available treatments that stop or reverse the progression of 
the disease. 
                                                
Fig:1.2 Comparison of a normal aged brain (left) and the brain of a person with                     
Alzheimer's (right). Differential characteristics are pointed out. 
 
Characteristics:  
                     The disease course is divided into four stages, with progressive patterns 
of cognitive and functional impairments 
Pre-dementia: 
                     The first symptoms are often mistakenly attributed to ageing or stress. 
Detailed neuropsychological testing can reveal mild cognitive difficulties up to eight 
years before a person fulfils the clinical criteria for diagnosis of Alzheimers disease. 
                     Subtle problems with the executive 
functions of attentiveness, planning, flexibility, and abstract thinking, or 
impairments in semantic memory(Memory of meanings and Concept relationships) 
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can also be symptomatic of the early stages of Alzheimers disease. Apathy can be 
observed at this stage, and remains the most persistent neuropsychiatric symptom 
throughout the course of the disease. 
Early stage: 
                     In people with Alzheimers disease the increasing impairment of 
learning and memory eventually leads to a definitive diagnosis. In a small portion of 
them, difficulties with language, executive functions, perception (Agnosia), or 
execution of movements (Apraxia) are more prominent than memory 
problems. Alzheimers disease does not affect all memory capacities equally. Older 
memories of the person's life (Episodic memory), facts learned (Semantic memory), 
and implicit memory (the memory of the body on how to do things, such as using a 
fork to eat) are affected to a lesser degree than new facts or memories.  
Moderate stage: 
                     Progressive deterioration eventually hinders independence; with 
subjects being unable to perform most common activities of daily living. Speech 
difficulties become evident due to an inability to recall vocabulary, which leads to 
frequent incorrect word substitutions (Paraphasias). Reading and writing skills are 
also progressively lost. Complex motor sequences become less coordinated as time 
passes and Alzheimers disease progresses, so the risk of falling increases During this 
phase, memory problems worsen, and the person may fail to recognise close 
relatives 
Advanced stage: 
                     During this last stage of Alzheimers disease, the person is completely 
dependent upon caregivers. Language is reduced to simple phrases or even single 
29 
 
words, eventually leading to complete loss of speech. Despite the loss of verbal 
language abilities, people can often understand and return emotional 
signals. Although aggressiveness can still be present, extreme apathy 
and exhaustion are much more common results. People with Alzheimers disease will 
ultimately not be able to perform even the simplest tasks without assistance. Muscle 
mass and mobility deteriorate to the point where they are bedridden, and they lose 
the ability to feed themselves. 
 
a. CAUSES OF THE DISEASE: 
                     The cause for most Alzheimer's cases is still essentially unknown 
(except for 1% to 5% of cases where genetic differences have been identified). 
Several competing hypotheses exist trying to explain the cause of the disease. The 
oldest, on which most currently available drug therapies are based, is the 
cholinergic hypothesis, which proposes that Alzheimers disease is caused by 
reduced synthesis of the neurotransmitter acetylcholine.                                
       
b. PATHOPHYSIOLOGY 
Neuropathology: 
                     Alzheimer's disease is characterized by loss of neurons and synapses in 
the cerebral cortex and certain sub cortical regions. This loss results in 
gross atrophy of the affected regions, including degeneration in the temporal 
lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus. Studies 
using MRI and PET have documented reductions in the size of specific brain regions 
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in people with Alzheimers disease as they progressed from mild cognitive 
impairment to Alzheimer's disease 
Disease mechanism: 
                     The amyloid hypothesis traditionally points to the accumulation of beta 
amyloid peptides as the central event triggering neuron degeneration. Accumulation 
of aggregated amyloid fibrils, which are believed to be the toxic form of the protein 
responsible for disrupting the cell's calcium ionhomeostasis, induces programmed 
cell death (Apoptosis). It is also known that Aβ selectively builds up in 
the mitochondria in the cells of Alzheimer's-affected brains, and it also inhibits 
certain enzyme functions and the utilisation of glucose by neurons. 
Genetics of the disease: 
                     The vast majority of cases of Alzheimer's disease are sporadic, 
meaning that they are not genetically inherited although some genes may act as risk 
factors. On the other hand around 0.1% of the cases are familial forms 
of autosomal dominant (not sex-linked) inheritance, which usually have an onset 
before age 65. This form of the disease is known as Early onset familial Alzheimer's 
disease 
c. DIAGNOSIS 
                     Alzheimer's disease is usually diagnosed clinically from the patient 
history, collateral history from relatives, and clinical observations, based on the 
presence of characteristic neurological and neuropsychological features and 
the absence of alternative conditions.
 
 Advanced medical imaging with Computed 
Tomography (CT) or Magnetic Resonance Imaging(MRI), and with Single Photon 
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Emission Computed Tomography  (SPECT) or Positron emission tomography (PET) 
can be used to help exclude other cerebral pathology or subtypes of 
dementia. Moreover, it may predict conversion from prodromal stages (Mild 
cognitive impairment) to Alzheimer's disease 
                                  
d. PREVENTION 
                    At present, there is no definitive evidence to support that any particular 
measure is effective in preventing Alzheimers disease. Global studies of measures to 
prevent or delay the onset of Alzheimers disease have often produced inconsistent 
results.                  Although cardiovascular risk factors, such as 
hypercholesterolaemia, hypertension, diabetes, and smoking, are associated with a 
higher risk of onset and course of Alzheimers disease, The components of 
a Mediterranean diet, which include fruit and vegetables, bread, wheat and 
other cereals, olive oil, fish, and  red wine, may all individually or together reduce 
the risk and course of Alzheimer's disease. 
Pharmaceutical Management: 
                    Five medications are currently approved by regulatory agencies such, as 
U.S.Food and Drug Administration (FDA) and the European Medicines 
Agency  (EMA) to treat the cognitive manifestations of Alzheimers disease. 
                       Acetylcholinesterase
6
 inhibitors (Tacrine, Rivastigmine, Galantamine 
and Donepezil) and the other (Memantine) is an NMDA receptor antagonist. No 
drug has an indication for delaying or halting the progression of the disease. The 
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most common  side effects are nausea and vomiting both of which are linked to 
cholinergic excess. 
 
1.5. PELLETS
17 
                    Pellets are defined as defined as multiple unit dosage forms which are 
small (0.5 mm to 1.5 mm), free flowing, spherical particulates formed by 
agglomeration of powders or granules of drug substances and excipients using 
appropriate processing equipment. Pellets are also used to describe small rods with 
aspect ratio of close to unity.  
1.5.1. Advantages: 
 Pellets are more advantageous in developing controlled release dosage forms 
other than single-unit dosage forms. 
 High flexibility in designing oral dosage forms 
 They can be divided into different strengths without formulation or process 
changes 
 They can be blended to deliver incompatible bioactive agents simultaneously 
and provide different release profiles at the same or different sites in the GI 
tract. 
 Pellets taken orally can disperse freely in the GI tract, maximize drug 
absorption, minimize local irritation of mucosa by certain irritant drugs  
 Reduced inter and intra-patient variability.   
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 1.5.2. Pelletization Techniques
18,19
: 
              The most commonly used and intensively investigated pelletization 
processes are powder layering, solution/suspension layering, and extrusion-
spheronization.  
a. Powder Layering:  
              Powder layering involves the deposition of successive layers of dry powder 
of drug or excipients or both on preformed nuclei or cores with the help of a binding 
liquid. Because powder layering involves the simultaneous application of the 
binding liquid and dry powder, it generally requires specialized equipment. The 
primary equipment-related requirement in a powder-layering process is that the 
product container should have solid walls with no perforations to avoid powder loss 
beneath the product chamber before the powder is picked up by the wet mass of 
pellets that is being layered on. 
 
       Fig:1.3. Scheme of steps involved in pelletization by Layering. 
      b. Solution Layering: 
              Solution/suspension layering involves the deposition of successive layers of 
solutions and/or suspensions of drug substances and binders on starter seeds, which 
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may be inert materials or crystals/granules of the same drug. In principle, the factors 
that control coating processes apply to solution or suspension layering and, as a 
result, require basically the same processing equipment. Consequently, conventional 
coating pans, fluid-bed centrifugal granulators, and Wurster coaters have been used 
successfully to manufacture pellets. The efficiency of the process and the quality of 
pellets produced are in part related to the type of equipment used. 
  
Fig:1.4 Scheme of stages involved in pelletization by suspension or solution 
Layering 
i. Conventional Coating Pan: 
                    In this technique the granules are placed in the coating pan and the 
coating solution is sprayed on the granules by atomizer with pressure. 
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                                        Fig:1.5 Fluidized Bed processing.  
 
ii. Fluidized Bed Processing: 
1. Beads are pushed through the coating column by hot air. 
2. While moving through the coating column, beads are sprayed with coating 
suspension. 
3. As beads circulate through the bed, the coating suspension dries and leaves a 
layer of solids on the bead. 
c. Extrusion-Spheronization: 
              It is a multistep process involving dry mixing, wet granulation, extrusion, 
spheronization, drying, and screening. The first step is dry mixing of the drug and 
excipients in suitable mixers followed by wet granulation, in which the powder is 
converted into a plastic mass that, can be easily extruded. The extruded strands are 
transferred into a spheronizer, where they are instantaneously broken into short 
cylindrical rods on contact with the rotating friction plate and are pushed outward 
and up the stationary wall of the processing chamber by centrifugal force. Finally, 
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owing to gravity, the particles fall back to the friction plate, and the cycle is repeated 
until the desired sphericity is achieved. 
 
 
 
   
 
 
 
 
 
 
Fig:1.6 Scheme of pelletization stages in Extrusion and Spheronization. 
d. Other Pelletization methods 
                    Other pelletization methods such as globulation, agitation and 
compaction (compression) are also used, although in a limited scale, in the 
preparation of pharmaceutical pellets. 
                    Globulation, or droplet formation, consists of two related processes, 
spray drying and spray congealing.  
                    Spray drying is the process in which drugs in the suspension or 
solution without excipient are sprayed into a hot stream to produce dry and more 
spherical particles. This process is commonly used for improving the dissolution 
rates, hence bioavailability of poorly soluble drugs.  
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                    Spray congealing is the process in which a drug is allowed to melt, 
disperse or dissolve in hot melts of gums, waxes or fatty acids, and is sprayed into 
an air chamber where the temperature is kept below the melting point of the 
formulation components, to produce spherical congealed pellets. Both immediate- 
and controlled-release pellets can be prepared in this process depending on the 
physicochemical properties of the ingredients and other formulation variables. 
                    Compression is one type of compaction technique for preparing pellets. 
Pellets of definite sizes and shapes are prepared by compacting mixtures or blends 
of active ingredients and excipients under pressure. The formulation and process 
variables controlling the quality of pellets prepared are similar to those used in tablet 
manufacturing.  
                    Balling is the pelletization process in which pellets are formed by a 
continuous rolling and tumbling motion in pans, discs, drums or mixers. The process 
consists of conversion of finely divided particles into spherical particles upon the 
addition of appropriate amounts of liquid.  
 
 
Capsules
12
 
                    Capsules are solid dosage forms in which the drug or a mixture of drugs 
is enclosed in hard or soft gelatin capsules. These shells made up of gelatin and this 
can be intended for oral administration. These are available in various sizes, shapes 
and capacity. 
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Types of capsules                 
  1.  Hard gelatin capsules                   2.  Soft gelatin capsules 
 
1. Hard gelatin capsules  
              These sizes are designed by in numbers. 
                                Table:1.1 Capsule sizes and their fill weights 
 
S.No 
 
Size of capsules 
 
Volume in ml 
 
Fill weight in mg 
1 000 1.37 615-1370 
2 00 0.95 430-950 
3 0 0.68 305-680 
4 1 0.50 225-500 
5 2 0.37 165-370 
6 3 0.30 135-300 
7 4 0.21 95-210 
8 5 0.13 60-130 
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2. Soft gelatin capsules: 
          These are classified depending upon the sizes and capacities. 
          The number represents capacities in minims 
1) Round-1,2,3,4,,5,6,7,8,9,28,40,40T,80T and 90T. 
2) Oval-1,2,3,4,,5,6, 7..5,10,12,16,20,40,60,80,85 and 110. 
3) Oblong-3,4,5,6,8,9.5,11,14,16,20,90 and 360. 
4) Tube-5,6,8,17.5,30A,30B,35,45,55,65,90,160,250,320 and 480. 
5) Misc-6, 17, 30, 35, 60 and 80. 
Capsules Standards and limits: 
Description: 
          It should comply with specifications of product. 
Content of active ingredients: 
          Limit: 90 to110% of label claim or as per in house limit. 
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Uniformity of weight
4
     
                                Table:1.2. Content uniformity limits(USP) 
 
                               
 
 
 
 
Disintegration test: 
 a. Hard gelatin capsules: 
           Disintegration time shall not be more than 30 min. 
 b. Soft gelatin capsules:  
           Disintegration time shall not be more than 60 min. 
c. Enteric capsule: 
           Acidic media –shall not disintegrate in 2hrs and in alkaline medium capsules 
shall disintegrate within 30 min. 
 
 
Average weight of 
capsules content 
 Percentage 
deviations allowed 
less than 130mg 10% 
130 to 320mg 7.5% 
320mg or more 5.0% 
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Standard length for hard gelatin capsules in mm 
                                      Table:1.3. Capsules lock length in mm. 
. 
 
 
 
 
 
 
Microbial limits: 
           Total microbial count, not more than 1000grams of the capsules shell. Atleast 
One gram of capsules shell be free from E.coli and Salmonella. 
Loss on drying: 
           Between 12.5% and 16% detrained on 0.3 gram of shell by drying in oven at 
105
0
C  for 4 hrs or to constant weight. 
Reason for selecting capsules: 
 The Galantamine in tablet form of three times dose per a day the prior art 
may cause problems in patients with swallowing difficulty for adults and childrens. 
Size Cap Body 
0 10.68-11.68 18.22-19.22 
1 9.51-10.51 16.22-17.22 
2 8.67-9.67 14.84-15.84 
3 7.73-8.73 12.98-13.98 
4 6.97-7.97 11.84-12.84 
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This drawback is avoided with the use of multiparticulate formulations, since they 
may be dispersed in liquids at the movement of the administration.  
 It should be kept in mind that pharmaceutical compositions formulated in 
tablets are subject to variations in their physicochemical properties such as hardness, 
disintegration time, and dissolution time and also on dissolution rate due to the 
compression process involved in their production. Such variations are of course 
undesirable in extended release Galantamine capsules, since the prediction of the 
dissolution rate is an extremely important factor for the efficiency of the 
formulation.  
  Finally Extended release multiparticulate formulations of Galantamine of the 
invention advantageously provide a better drug release at the gastrointestinal tract 
compared with single tablets formulations and the dosing frequency will be reduced.                         
The attractiveness of these dosage forms is due to awareness to toxicity and 
ineffectiveness of drugs when administered or applied by conventional method in 
the form of tablets, capsules, injectables, ointments etc. Usually conventional dosage 
form produce wide ranging fluctuation in drug concentration in the blood stream and 
tissues with consequent undesirable toxicity and poor efficiency.  
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II.LITERATURE REVIEW 
 Timo Erkinjuntti, et al 28(2002)  Proved robust evidence for the 
effectiveness of cholinergic treatments such as galantamine (Reminyl IR) in 
AD suggests its potential use in the treatment of dementias related to 
preclinical evidence supports this rationale. Galantamine, which has a unique 
dual cholinergic mode of action, may be of particular benefit in Vascular 
Dementia and AD with Cognitive Vascular Dementia. 
 Patrick Vigneault, Sarah Bourgault, et al 29(2012) Galantamine is a 
reversible inhibitor of acetylcholinesterase and an allosteric-potentiating 
ligand of the nicotinic acetylcholine receptors. It is used for treating mild-to-
moderate Alzheimer's disease. Interestingly, QT interval prolongation on the 
electrocardiogram (ECG), malignant ventricular arrhythmias and syncope 
have been reported with Galantamine. 
 Alexis Kays Leonard, et al 30(2005) studied and developed an intranasal 
(IN) formulation of the acetyl cholinesterase inhibitor galantamine, Various 
approaches were examined to this end, including adding co-solvents, 
cyclodextrins, and counterion exchange. Of these, replacement of bromide 
ion with lactate or gluconate, resulted in a dramatic drug solubility increase, 
more than 12-fold. NMR confirmed the molecular structure of new drug salt 
forms. The in vivo studies confirmed that IN galantamine achieves systemic 
blood levels comparable to those of conventional oral administration
 .
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 Khatavkar UN, et al 31(2011) Developed and evaluated in vivo of novel 
monolithic matrix mini tablets approach to control the release of 
Galantamine Hydrobromide (GAH) in comparison with desired release 
profile to the Innovator formulation Razadyne(®) ER capsules. The direct 
compression method was employed for preparation of matrix mini tablets as 
against reservoir multiparticulate pellets of innovator formulation. It was 
found that increase in the concentration of high viscosity 
hydroxypropylcellulose (HPC) results reduction in release rate. In vivo 
prediction was done by Wagner-Nelson method. Prediction errors were 
estimated for C(max) and area under curve (AUC) and found to be not 
exceeding 15%. These results suggest that novel monolithic matrix approach 
could be suitable technique to formulate controlled release GAH. 
 Patent number-7955622 32: Controlled Release galantamine formulations, 
including controlled release particles, pellets, granules, and spheres are 
prepared by using sugar pellets as core, HPMC as Binder cum retardant and 
Ethyl Cellulose as Sustain Polymer. 
 Ben Seltzer, et al 33(2010) An extended release form of the cholinesterase 
inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly 
to increase adherence to medication regimes in patients with mild-to-
moderate Alzheimer’s disease (AD). Except for predicted differences in 
(Cmax) and tmax, comparable doses of once daily galantamine-ER and regular, 
immediate release galantamine, (galantamine-IR), are pharmacologically 
equivalent. A 24-week randomized, double-blind, placebo-and active-
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controlled, multicenter phase III trial, which compared galantamine-IR, 
galantamine-ER and placebo in subjects with mild to moderate  score range, 
Since its release onto the market galantamine-ER has enjoyed wide 
popularity and a recent surveillance study suggests that it has the highest 1-
year persistence rate of all the ChEIs. 
 Olin J, Schneider L, et al 34(2001) was isolated from several plants, 
including daffodil bulbs, but is now synthesized. Galantamine is a specific, 
competitive, and reversible acetylcholinesterase inhibitor., which were 
similar to those seen in earlier antidementia AD trials, and consisted 
primarily of mildly to moderately impaired outpatients. In this magnitude for 
the cognitive effect is similar to other cholinesterase inhibitors including 
donepezil, rivastigmine, and tacrine.  
 Guk-Hee Suh, et al 35(2004) Studied in the Korean population rapidly aging 
and the nurnber of Koreans with Alzheimer's disease (AD) steadily growing, 
treatment of AD is becoming an increasing concern. Galantamine 
hydrobromide, a dual acetylcholinesterase inhibitor and allosteric modulator 
of nicotinic receptors, is being studied in the treatment of the disease. 
 Hugo Geerts, et al 36(2005) suggest a role for cholinergic stimulation, 
especially the 7-nicotinic acetylcholine receptors (nAChR), amyloid 
mediated neurotoxicity. There is substantial evidence that these effects occur 
by upregulation of the protective protein bcl-2 and are mediated via 7-
nicotinic acetylcholine receptors. suggesting a neuroprotective effect for 
galantamine mediated by 7-nicotinic receptors are worthy. 
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 Patent No-0142193 37:  substantially claims that galantamine formulations 
include Microcrystalline cellulose, lactose, starch colloidal silicon dioxide, 
crospovidone, Hydroxy propyl methyl cellulose, propylene glycol, talc and 
titanium dioxide. 
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III. AIM AND OBJECTIVE 
                   The aim and objective of the present study was to develop extended 
release Galantamine capsules and these were compared with the Innovator product 
(Razadyne). 
 
The purpose of the present work was aimed at the following objectives. 
 The dosing frequency is also reduced by formulate into capsules. 
 Even though in market Galantamine tablets and gels is available we can 
formulate pellets because of pellets are having good flow properties in 
intestine and less cost of production for formulation. 
 The main aim of the present study was to extended release Galantamine 
capsules of 16 hours release for to reduce the dosing frequency when 
compared with the Immediate Release tablet for treating Alzheimer. 
 To achieve this goal we have to formulate and evaluate the capsules. The 
formula will be finalized by comparing the in-vitro dissolution profile with 
that of the marketed product. 
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IV. PLAN OF WORK 
 Step: 1 Preformulation Study 
 API Characterization 
o Physical Appearance 
o Solubility studies 
o  Sieve Analysis 
 Drug-Excipient Compatibilty Studies 
o Physical Compatibility 
o FT-IR Spectrophotometry 
 Analytical Method Development 
 Step: 2  Selection Of Coating Technology 
 Step: 3  Formulation Development 
 Step: 4  Evaluation of Pellets 
 Physical Description 
 Sieve Analysis 
 Bulk Density and Tap Density 
 Percentage Moisture Content 
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 Step: 5 Evaluation of Capsules 
 Weight Variation 
 Content Uniformity 
 Lock Length 
 Assay by HPLC 
 Dissolution by HPLC 
 Step: 6  Comparison of Dissolution profile of trial formulations 
with    Innovator. 
 Step: 7  To perform Stability Studies of Selected Formulation. 
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V. DRUG PROFILE
 
Galantamine
25
:  
                       Galantamine is a cholinesterase inhibitor that has been used to reverse 
the muscular effects of gallamine triethiodide and tubocurarine, and has been studied 
as a treatment for Alzheimer’s disease and other central nervous system disorders. 
Chemical IUPAC Name: 
(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-
benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydro bromide.  
 
                            
                                    Fig: 5.1 Molecular Structure 
Chemical Formula: C17H21NO3 
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Molecular Weight: 287.15  
State: White Crystalline Solid 
Melting Point: 269-270
0
C 
Partition Coefficient: Log P =1.39 
Dissociation Constant:  Pka= 8.2 
Purity:  ≥98%. 
BCS Class: II 
Solubility: 
                  Sparingly soluble in aqueous buffers and water, soluble in Sodium 
hydroxide 
Chemical Class:  Benzofurans derivative. 
Therapeutic Class: Cholinesterase Inhibitor. 
Storage: 
                  Store the drug in a closed container at room temperature, away from heat, 
moisture, and direct light.  
Stability:  ≥2years at 250C 
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Indication:  
                  For the treatment of mild to moderate dementia of the Alzheimer's type 
and also been investigated in patients with mild cognitive impairment, who did not 
meet the diagnostic criteria for Alzheimer's disease. 
Pharmacology: 
                  Galantamine is a parasympathomimetic, specifically, a reversible 
cholinesterase inhibitor. It is indicated for the treatment of mild to moderate 
dementia of the Alzheimer's type. An early pathophysiological feature of 
Alzheimer's disease that is associated with memory loss and cognitive deficits is a 
deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the 
cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to 
exert its therapeutic effect by enhancing cholinergic function. This is accomplished 
by increasing the concentration of acetylcholine through reversible inhibition of its 
hydrolysis by acetyl cholinesterase.  
Mechanism of action: 
                  Galantamine's proposed mechanism of action involves the reversible 
inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, 
leading to an increased concentration of acetylcholine at cholinergic synapses. 
Galantamine also binds allosterically with nicotinic acetylcholine receptors and may 
possibly potentiate the action of agonists (such as acetylcholine) at these receptors. 
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Dosage: 
                  Dosing differs accordingly with the dosage form, and also indication. 
5.1. PHARMACOKINETICS:        
5.1.1.Absorption:               
                  Galantamine is rapidly and completely absorbed with time to peak 
concentration about 1 hour. Bioavailability of the capsule was the same as the 
bioavailability of an oral solution. Food did not affect the AUC of Galantamine but 
Cmax decreased by 25% and Tmax was delayed by 1.5 hours. The mean volume of 
distribution of Galantamine is 175 L. 
5.1.2. Distribution: 
                  The plasma protein binding of Galantamine is 18% at therapeutically 
relevant concentrations. In whole blood, Galantamine is mainly distributed to blood 
cells (52.7%). The blood to plasma concentration ratio of Galantamine is 1: 2. 
5.1.3. Metabolism: 
                  Galantamine is metabolized by hepatic Cytochrome P450 enzymes, 
glucuronidated, and excreted unchanged in the urine. In vitro studies indicate that 
cytochrome CYP2D6 and CYP3A4 were the major cytochrome P450 isoenzymes 
involved in the metabolism of Galantamine, and inhibitors of both pathways 
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increase oral bioavailability of Galantamine modestly O-demethylation, mediated by 
CYP2D6 was greater in extensive metabolizers of CYP2D6 than in poor 
metabolizers. In plasma from both poor and extensive metabolizers, however, 
unchanged Galantamine and its glucuronide accounted for most of the sample 
radioactivity. 
5.1.4. Excretion: 
                  Galantamine Hydro bromide Extended Release capsules on oral 
administration, about 20% of the dose was excreted as unchanged Galantamine in 
the urine in 24 hours, representing a renal clearance of about 65 mL/min, about 20–
25% of the total plasma clearance of about 300 ml/min. 
Elimination half-life:  7 hours, allowing once daily administration in a clinical 
setting. 
Special Populations: 
Elderly 
                 Data from clinical trials in patients with Alzheimer's disease indicate that 
Galantamine concentrations are 30–40% higher than in healthy young subjects.  
CYP2D6 Poor Metabolizers  
                 Approximately 7% of the normal population has a genetic variation that 
leads to reduced levels of activity of CYP2D6 isozyme. Such individuals have been 
referred to as poor metabolizers. After a single oral dose of 4 mg or 8 mg 
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Galantamine, CYP2D6 poor metabolizers demonstrated a similar Cmax and about 
35% AUC increase of unchanged Galantamine compared to extensive metabolizers. 
Hepatic Impairment: 
                 Following a single 4 mg dose of Galantamine tablets, the 
pharmacokinetics of Galantamine in subjects with mild hepatic impairment (n=8; 
Child-Pugh score of 5–6) were similar to those in healthy subjects. In patients with 
moderate hepatic impairment (n=8; Child-Pugh score of 7–9), Galantamine 
clearance was decreased by about 25% compared to normal volunteers. Exposure 
would be expected to increase further with increasing degree of hepatic impairment. 
Gender and Race: 
                 No specific pharmacokinetic study was conducted to investigate the effect 
of gender and race on the disposition of Galantamine Hydrobromide, but a 
population pharmacokinetic analysis indicates (n= 539 males and 550 females) that 
galantamine clearance is about 20% lower in females than in males (explained by 
lower body weight in females) and race (n= 1029 White, 24 Black, 13 Asian and 23 
others) did not affect the clearance of Galantamine Hydrobromide.                       
Renal Insufficiency: 
                   Following a single 8 mg dose of Galantamine tablets, AUC increased by 
37% and 67% in moderate and severely renal-impaired patients compared to normal 
volunteers. 
56 
 
 
 
5.2. DRUG-DRUG INTERACTIONS 
Use with Anticholinergics: 
                   Galantamine Hydrobromide has the potential to interfere with the 
activity of anticholinergic medications. 
Use with Cholinomimetics and Other Cholinesterase Inhibitors: 
                   A synergistic effect is expected when cholinesterase inhibitors are given 
concurrently with succinylcholine, other cholinesterase inhibitors, similar 
neuromuscular blocking agents or cholinergic agonists such as bethanechol. 
A) Effect of Other Drugs on Galantamine 
Cimetidine and Ranitidine 
                  Galantamine was administered as a single dose of 4 mg on day 2 of a 3-
day treatment with either Cimetidine (800 mg daily) or Ranitidine (300 mg daily). 
Cimetidine increased the bioavailability of Galantamine by approximately 16%. 
Ranitidine had no effect on the PK of Galantamine. 
5.3. INNOVATOR CHARACTERIZATION 
Brand Name                     : Razadyne ER Capsules 
Batch No                             OJG001 
Mfg by:                                Ortho-Mcneil Neurologics, Belgium, Olen 
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Physical Characteristics 
 Capsule Size                     : 1 
 Capsule Colour                : Caramel Colour Cap and body 
 Pellets Shape                     : Spherical 
 Pellets Colour                   : Shining White 
Average Fill Weight         : 294.37mg 
% Moisture Content        : 0.8 
Assay                                 : 101.7% 
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VI. MATERIALS AND METHODS 
 
                                         Table:6.1 Materials List 
Ingredients Manufacturer Category 
Galantamine 
Aurobindo Pharma, 
Hyderabad 
API 
HPMC E5 
Colourcon, 
Goa. 
Retardant 
PEG 6000 
Clarient, 
Mumbai. 
Solubilizer 
Ethyl Cellulose 
Shandong,  
China. 
Extended Release 
Coating 
Sugar Spheres 
Prime Health Care Ltd, 
Chennai. 
Core pellets 
Isopropyl Alcohol 
Rankem, 
Faridabad. 
Solvent 
Water 
Rachem,  
Hyderabad. 
Solvent 
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6.1.1. EXCIPIENT PROFILE
 20
 
Table:6.2   HYPROMELLOSE
 
Synonyms Benecel, HPMC, Methocel, Hydroxy propyl methyl 
cellulose 
Description White or creamy white fibrous or granular, odourless, 
tasteless powder 
Functional Categories Coating agent, film former, rate controlling polymer for 
sustained release, stabilizing agent, suspending agent 
viscosity builder  
Solubility Soluble in cold water, forming a viscous colloidal 
solution, practically insoluble in mixtures of ethanol and 
dichloromethane, mixtures of alcohol and water 
pH 5.5-8.0 for a 1%w/w aqueous solution 
Bulk Density  0.341 g/cm
3
 
Tapped Density  0.557 g/cm
3
 
Melting Point Browns at 190-200
o
C   
Chars at 225-230
o
C 
Moisture Content Absorbs moisture from the atmosphere 
Stability and Storage 
Conditions 
Stable between pH 3-11, should be stored in a well-closed 
container in a cool and dry place 
Incompatibility Incompatible with some oxidizing agents 
Applications High viscosity grades may be used to retard the release of 
drugs from a matrix at  levels of 10-80%w/w in tablets 
and capsules 
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                                     Table:6.3 SUGAR SPHERES 
Synonyms Non-pareil; Non-pareil seeds; NPTAB; Nu-Core; Nu-
Pareil PG; sugar seeds; Suglets 
Description Approximately spherical granules of a labeled 
nominal-size range with a uniform diameter and 
containing not less than 62.5% and not more 
than 91.5% of sucrose, calculated on the dried basis. The 
remainder is chiefly starch 
Functional Categories Tablet and capsule diluent. 
Solubility solubility in water varies according to the sucrose-to-
starch ratio. The sucrose component is 
freely soluble in water, whereas the starch component is 
practically insoluble in cold water. 
Density 1.57–1.59 g/cm3 for Suglets less than 500 μm in size; 
1.55–1.58 g/cm3 for Suglets more than 500 μm in size. 
Storage Sugar spheres are stable when stored in a well-closed 
container in a cool, dry place. 
Applications Sugar spheres are mainly used as inert cores in capsule 
and tablet formulations, particularly multiparticulate 
sustained-release formulations 
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Table:6.4 POLY ETHYLENE GLYCOL-6000 
Synonyms Polyethylene glycol, Macrogol. 
Chemical Name ά- Hydro-ω-Hydroxypoly-(oxy-1,2-ethanediyl)   
Description Their odor is faint and sweet. Grades of 6000 and above are 
available as fee-flowing milled powders 
Functional Categories USP-Suppository base, Solvent, tablet and/or capsule 
lubricant, ointment base and  pharmaceutical aid.                            
Solubility All grades are soluble in water and miscible in all 
proportions with other PEGs (after melting if necessary), 
aqueous solutions of higher molecular weight grades may 
form gels. 
Melting point 
 
PEG -6000: 55-63
0
C 
PEG -1000: 37-40
0
C   
PEG -1500:44-48
0
C               
Storage Oxidation may occur if PEGs are exposed for long periods to 
temperatures exceeding 50
0
C. Storage under nitrogen will 
reduce the possibility of oxidation. 
Incompatibilities With solid grades of, Phenobarbital forms water in soluble 
complex (by hydrogen bonding) 
Applications Gelling agent, Solubilizer, Tabelt binder and Tablet film 
coating. 
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Table:6.5 ETHYL CELLULOSE 
Synonyms Ethyl cellulose, Ethocel 
Description A tasteless free flowing white to light powder. 
Functional Categories  Tablet binder, coating agent 
Solubility Insoluble in water, glycerin and propylene glycol but 
insoluble in varying degrees in certain organic solvents, 
depending upon the ethoxyl content. 
Stability and storage 
condition 
 
It is resistant to alkalis both dilute and concentrated and 
to salt solutions. It is more sensitive to acidic materials 
than are cellulose esters 
Ethylcellulose should be stored between 70C and 320C 
in a dry area away from all sources of heat. Store in a 
well closed container 
Incompatibilities Incompatable with paraffin wax and microcrystalline 
wax 
Applications Tablet binder, Tablet coating material, Thickening agent 
in creams and lotions or gel. 
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Table:6.6 ISO PROPYL ALCOHOL 
Synonyms Isopropanol, Alcohol Isopropylieum , petrohol,  
dimethylcarbinol,  2-propan-2-ol, Sec-propyl alcohol. 
Description 
 
Transparent, colorless, mobile, volatile, flammable liquid 
with a characteristic, spirituous odor resembling that of a 
mixture of ethanol and acetone and a slightly bitter taste. 
Functional Categories  Local disinfectant. 
Melting point 88.5
0
C 
Stability and storage 
condition 
Store in a tight container remote from heat and protected 
from light. 
Incompatibilities Oxidizing agents like hydrogen peroxide and nitric acid 
decompose isopropyl alcohlol. It may be slated out form 
aqueous mixtures by the addition of sodium salts etc. 
Applications Disinfectant 
Degreasing in Lotions 
Solvent for Film Coating Cosmetics  
Tablet Granulation  
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6.2. EQUIPMENTS USED 
Table No:6.7 Equipments List 
NAME MANUFACTURER 
Electronic Weighing Balance Essae DS-852, Bangalore. 
Fluidised Bed Processor Pharmatech UFBM-3, Vasai. 
Mechanical Stirrer REMI Electrotechnik RQ1291D,                                                                                                      
Thane. 
Capsule Filling Machine Pam Pharmaceutical MFD112, 
Mumbai. 
KF Titrator Metrohm, 787 KF Titrino, India. 
Tray Drier Millenium Equipment METD-64, 
Hyderabad. 
UV Apparatus(Double Beam) Shimadzu UV2450, USA. 
Dissolution Apparatus Electrolab ED2AL, Mumbai. 
HPLC Apparatus Shimadzu LC-2010C, USA. 
Electronic Sieve shaker SWECO, Mumbai. 
Automatic capsule filling 
machine 
Rimek formulations, Mumbai. 
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6.3 EXPERIMENTAL WORK 
6.3.1. PREFORMULATION STUDIES
10
: 
a. API Characterization: 
                           The overall objective of preformulation testing is to generate 
information useful in developing the formulation which is stable and bioavailable. 
Further the use of preformulation parameters maximizes the chances in formulating 
an acceptable, safe, efficacious and stable product. For any drug substance to 
formulate into a dosage form, it is necessary to study the physicochemical properties 
of the bulk drug like physical appearance, solubility, melting point, particle size and 
compatibility. 
 Physical Appearance: 
                           The appearance of the API is done by visual observation 
Solubility Studies: 
                            The solubility of drug is an important physicochemical property 
because it affects the bioavailability of the drug, the rate of drug release into the 
dissolution medium, and consequently the therapeutic efficacy of the pharmaceutical 
product. The solubility of a material is usually determined by the equilibrium 
solubility method, which employs a saturated solution of the material, obtained by 
stirring an excess of material in the solvent for a prolonged period until equilibrium 
is achieved. 
Sieve Analysis: 
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                                The main aim of sieve analysis is to determine the different size 
of drug particles present. A series of standard sieve are stacked one above the other 
so that sieves with larger pore size (less sieve number) occupy top position followed 
by sieves with smaller pore size (greater sieve number towards the bottom). 
Procedure: 
                              A series of sieves are arranged in the order of their decreasing 
pore diameter (increasing sieve number) such as sieve number 20, 30, 40, 60, 100 
and 200. 100 grams of drug is weighed accurately and transferred to sieve number 
20 which were kept on top. The sieves are shaken for about 5-10 minutes. Then the 
drug retained on each sieves is taken, weighed separately and amount retained is 
expressed in terms of percentage. 
b. Drug - Excipient Compatibility Studies: 
                   Compatability studies are carried out to study the possible interactions 
between Galantamine and other active ingredients 
Procedure:  
                   The compatibility studies are carried out by taking a mixture of drug and 
excipients at the ratio in which they are expected to be present in the innovator 
product. A part of mixture can be exposed to different storage conditions like 
40
o
C±2
o
C /75% RH ±5%  and control samples were to be kept at 2-8
o
C. They are 
tested with respect to their physical and chemical aspects. These samples are 
collected at regular intervals and subjected to FT-IR. 
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Table:6.8 Conditions for compatibility studies
24
 
S.No.    Storage Condition Samples packed  in Sampling Periods in 
weeks 
1 
 
 
 
Accelerated 
40 
o
C±2
  o
C /75% RH ±5%  
 
 
3 Double polythene 
bags 
 
 
1W,2W,3W,4W 
 
 
2 Refrigeration   2-8
o
C 
1 Double polythene 
bag + 1 glass vessel 1W,2W,3W,4W, 
   
 
FT-IR Spectrophotometric Method: 
           It is performed by Potassium bromide pellet method.  Potassium bromide is 
dried in oven at 45
°
C before analysis. The pure drug is triturated with Potassium 
bromide and pellet is prepared by setting the pressure to 100 kg/cm
2
 for 2 minutes. 
The obtained pellet is analyzed in Burker FTIR Tensor Model, Germany. Potassium 
bromide background was obtained initially before analysis of test samples. The same 
procedure is repeated for analysis of drug and Hydroxy Propyl Methyl Cellulose E5, 
Ethyl CelluloseN45, also drug and excipient mixture free from moisture content are 
used for analysis.  
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6.3.2. Analytical Method Development: 
a. Determination of absorption maxima (λmax) for Galantamine  
          Standard stock solution containing 100 μg/ml of Galantamine Hydrobromide 
was prepared in Distilled water. From the stock, different aliquots were taken and 
diluted to 10 ml mark with same solvent to obtain series of concentrations. The 
solutions were scanned on Spectrophotometer in the UV range 200-400 nm. 
Galantamine Hydrobromide showed absorbance maxima at 289 nm. 
b. Preparation of standard curve for Galantamine Hydrobromide . 
                       100 mg of Galantamine Hydrobromide was dissolved in 100 ml 
calibrated volumetric flask and completing to volume with P
H
 6.5 phosphate Buffer. 
From this 10ml pipette out in 100 ml calibrated volumetric flask and dilution was 
made with P
H
 6.5phosphate Buffer. From this solution 2 ml, 4ml, 6ml, 8ml…up to 
10ml was pipette out in different 10 ml volumetric flask and this was finally diluted 
with P
H
 6.5phosphate Buffer to 10ml. The absorbance was noted max of 289nm.  
 
6.3.3. METHOD OF MANUFACTURING 
a. Fluidised Bed Processing: 
Raw Material Dispensing: 
                Accurately weighed quantities of raw materials, measured quantities of 
solvents are dispensed.  
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Coating Solution Preparation: 
                HPMC E5 is dissolved in specific quantity of Water Add all other 
ingredients along with drug are added to it, which are stirred under mechanical 
stirrer at 1600-1900RPM.The above two solutions are mixed by stirring. 
Filtration: 
               The solution is filterd through #150 mesh, to remove any lumps or visible 
particles. 
Drug Loading: 
                Accurately weighed sugar spheres (cores) are transferred into Fluid Bed 
Processor (FBP). These cores are coated with drug solution uniformly. 
Sieving: 
                Finally these dried pellets are sieve to obtain pellets of uniformity with 
required size. 
Barrier Coating: 
                 HPMC E5 is dissolved in specific quantity of Water. PEG-6000 are added 
to it, which are stirred under mechanical stirrer at 1600-1900RPM.Transfer the Drug 
loaded pellets to FBP for Barrier coating. 
Extended Release Coating: 
              Ethyl Cellulose N45 is dissolved in specific quantity of Iso Propyl Alcohol, 
PEG-6000 are added to Water, which are stirred under mechanical stirrer at 1600-
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1900RPM. The above two solutions are mixed by stirring. Transfer the barrier 
Coated pellets to FBP for ER coating. 
 
Sieving and Drying: 
                Finally these dried pellets are sieved to obtain pellets of uniformity with 
required size and dried. 
Capsule Filling:      
                The weight of pellets equivalent to 24mg Galantamine are filled into hard 
gelatin capsules of size.1 by capsule filling machine.  
 
Process Control Parameters: 
 Spray Gun  :   Needle  
 Spray Type  :  Bottom spray 
 Spray Rate  :  5ml/min 
 Spray Pump RPM :  2-6 rpm 
 Inlet Temperture :  39 °C 
 Bed Temperature :  37 °C 
 Outlet Temperture :  31-33 °C 
 Air Presssure  :  1Kg/cm
2 
6.3.4. Formulation Development
 
                 Galantamine Hydrobromide extended release capsules were prepared. 
The process was displayed in the following flow chart. 
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                   MANUFACTURING PROCESS FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Galantamine Hydro 
bromide 
Sugar core 
Binder Solution: 
HPMC 
Isopropyl Alcohol 
Water 
Barrier Coating 
Solution 
HPMC E5 
PEG 6000 
Purified water 
Sizing and 
sieving 
 
 
Drug loading 
FBP 
 
Drying in  
       Tray dryer 
Sieving in #16  
and  #20 
 
Sieving in #18 
and  #20 
 
Coating in FBC 
 
Drying in  
       Tray dryer 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig:6.1. Manufacturing flow chart for extended release capsules 
 
FORMULATION TRAILS 
Formulation studies Galantamine Hydrobromide extended release capsules are based 
on pre formulation data of various excipients were selected and their compilation 
was shown in the following Table.6.9. 
 
 
           
Filling of pellets into 
capsule No.1 
Sieving in #18  
And #22 
 
ER Coating 
Solution 
Ethyl Cellulose 
PEG 6000 
IPA 
Purified water 
Coating in FBC 
        
Drying in  
       Tray dryer 
73 
 
 
  Table No. 6.9 Formulae and their quantities as per w/w: 350grams Batch 
 
S.No Ingredients F1  F2 F3 F4 F5 F6 F7 F8 F9 
1 Galantamine 
Hydrobromide   
35.87 35.87 35.87 35.87 35.87 35.87 35.87 35.87 35.87 
2 Sugar 
Pellets(18≠22) 
273.2 273.2 273.2 273.2 273.2 273.2 273.2 273.2 273.2 
3 HPMC E5 8 9 10 11 12 16 15 14.5 14 
4 I.P.A 239 239 239 239 239 239 239 239 239 
4 Water 239 239 239 239 239 239 239 239 239 
Barrier Coating 
5 HPMC  E5 15 12 14 10 14 14 14 14 14 
6 P.E.G-6000 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 
7 Purified Water 260 260 260 260 260 260 260 260 260 
ER coating 
10 Ethyl cellulose 17.5 16.5 15.5 8 8 12 9.5 10 10.5 
11 P.E.G-6000 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 
12 I.P.A 197.4 197.4 197.4 197.4 197.4 197.4 197.4 197.4 197.4 
13 Purified Water 296 296 296 296 296 296 296 296 296 
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                    Pellets were evaluated by physical and chemical parameters. 
Characteristics   like Bulk density, Tapped density, Compressibility index, 
Hausner’s ratio, Angle of repose, sieve analysis and assay carried out for core 
pellets, coated pellets. The results were presented in the form of Table.7.16 in 
results. 
Loading of Galantamine Hydrobromide  Pellets in Capsules 
       To prepare Galantamine capsules 24mg by taking Galantamine 
Hydrobromide   pellets 24 mg from the formulation F9 is taken and filled. 
Procedure 
1.        Before filling pellets into capsules the parameters like Bulk density, Tappered          
           density, Angle of repose, are evaluated. 
2. Size‘1’ capsules were selected for capsule formulation which has Purple 
color  capsule shell. 
3. The pellets were loaded in hard gelatin capsules No.1 with Automatic 
capsule  filling machine. 
4. Coated pellets were transferred into capsules by spreading it into equal 
quantities  equivalent to 24 mg Galantamine Hydrobromide. 
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 Stability Study
24
 
                          For all the pharmaceutical dosage forms it is important to determine 
the stability of the dosage form. This will include storage at both normal and 
exaggerated temperature conditions, with the necessary extrapolations to ensure the 
product will, over its designed shelf life, provide medication for absorption at the 
same rate as when originally formulated. The design of the formal stability studies 
for the drug product should be based on the knowledge of the behavior and 
properties of the drug substance and formal stability studies on the drug substance. 
Specification which is list of tests, reference to the analytical procedures and 
proposed acceptance criteria, including the concept of different acceptable criteria 
for release and shelf life specifications, is addressed in ICH CS L6AS and IS6B. 
Storage conditions
24
  
Stability samples are stored at 
Accelerated   : 40±2°C/75±5% RH 
Intermediate: 30±2°C/65±5% RH 
Long term     : 25±2°C/60±5% RH 
Testing Intervals for  
Accelerated: Initial, 1, 2, 3 and 6 months 
Long term: Initial, 3, 6, 9, 12, 18, 24 and 36 months. 
Intermediate: Initial, 3, 6, 9 and 12 months. 
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The formula of F9 was optimized and selected for evaluation studies. Further 
stability study was done for F9. 
  In general significant change for a drug product is defined as 
 A 5% change in assay from its initial value or failure to meet the acceptance 
criteria for when using biological or immunological procedures. 
 Any degradation products exceeding its acceptance criterion. 
 Failure to meet the acceptance criterion for appearance, physical attributes, 
and functionality test. e.g. size, shape and dose delivery per activation 
however some changes in physical attributes may be accepted under 
accelerated condition and as appropriate for the dosage form. 
 Failure to meet the acceptance criterion for pH. 
 Failure to meet the acceptance criterion for dissolution for 12 dosage units.  
            Studies like moisture content, assay, dissolution studies were carried out for 
a period of 2 months. Initial stage, at the end of first month and second month, the 
above said parameters were carried out at 25
O
C/60%RH, 30
O
C/65% RH and 
40
O
C/75%RH.                    
6.3.5. EVALUATION OF CAPSULES
 
Weight variation test
26 
 Individual weights of 20 capsules were taken and the average weight was calculated 
by using the following formula. 
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                                  (Weight of capsule-Average weight)   
   Weight variation = ----------------------------------------------- ×100 
                                        Average weight of capsules 
      
Weight variation should not be more than 5 %. 
 Lock Length
26
 
             It was tested by using Vernier calipers. 
Disintegration 
              The compendial disintegration test for hard and soft capsules follows the 
same procedure and uses the same apparatus. The capsules are placed in the basket 
rack assembly, which is repeatedly immersed 30 times per minute into a 
thermostatically controlled fluid at 37ºc and observed over the time described in the 
individual monograph. To fully satisfy the test the capsules disintegrate completely 
into a soft mass having no palpably firm core, and only some fragments of the 
gelatin shell.  
 Dissolution
26
  
  Procedure 
            For capsules place 500ml of dissolution medium in each vessel and allow the 
medium to equilibrate to a temperature of 37 ± 0.5 ºC. Place one capsule in each of 
the Paddle and operate the apparatus at 50 rpm for specific time. With draw 10ml of 
the solution from each vessel and replace with equal volume of fresh dissolution 
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medium at specific time intervals. Filter the solution through 0.45microns membrane 
filter and discard first few ml of the filtrate. Dissolution study was carried out in pH 
6.5 buffer for 0
st
, 2
th
, 6
th
, 12
th 
and 16
th
 hours and
 
assay was done by HPLC method.  
                            Table: 6.10. Dissolution Parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay by HPLC
 27
 
Mobile Phase Reagents: 
Solution A: Methanol and buffer Solution (1:19) AR Grade 
Solution B: Acetonitrile  and methanol(19:1) HPLC grade 
 
Apparatus USP Type-II (Paddle) 
Volume 500 ml 
RPM 50 
Medium  pH 6.5 phosphate Buffer at 37ºC 
Drug release time 0
th
 Hour 
 2
th 
Hour 
 6
th 
Hour 
 12
th 
Hour 
 16
th
 Hour 
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Preparation of P
H
 6.8 Phosphate buffer: 
                5.34g/L of dibasic sodium phosphate dehydrate in water. Adjust with 
phosphoric acid to a pH of 6.5 
Preparation of Mobile Phase: 
                  Filtered and degassed mixture of buffer and acetonitrile in the ratio of 
30:70 v/v is prepared. 
Preparation of Blank Solution: 
                   Accurately weighed quantity of about 33mg of placebo powder is 
transferred into 100ml volumetric flask, 60ml diluents is added, sonicated for 
15minutes and made upto the mark with diluent.  5.0ml of the resulting solution is 
transferred into a 50ml volumetric flask and made up to the mark with diluent.  The 
solution is filterd through 0.45µm Nylon filter. 
 
Preparation of Standard Solution: 
                    Accurately weighed quantity of about 24mg of Galantamine 
Hydrobromide working standard is transferred into 100ml volumetric flask, 60ml 
diluents is added, sonicated for 15minutes and made up to the mark with diluent. 
5.0ml of the resulting solution is transferred into a 50ml volumetric flask and made 
up to the mark with diluents. The solution is filtered through 0.45µm Nylon filter. 
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Preparation of Sample Solution: 
                  Accurately weighed quantity of powdered pellets equivalent to 24mg of 
Galantamine Hydrobromide is transferred into 100ml volumetric flask, 60ml 
diluents is added, sonicated for 15minutes and made upto the mark with diluent. 
5.0ml of the resulting solution is transferred into a 50ml volumetric flask and made 
upto the mark with diluent. The solution is filterd through 0.45µm nylon filter. 
Chromatographic Conditions: 
Column                         : Hypersil BDS C18, 4.6mm×10cm; 3-µm L1 packing  
Flow Rate                      : 1.5 ml/min 
Wave Length                 : 230 nm 
Column Temperature     : 35°C 
Injection Volume           : 20µl 
Run Time                      : 6minutes. 
System Suitability: 
                    The peak responses are recorded for standard solution. The relative 
standard deviation for five replicate standard solution injections should not be more 
than 2%. The tailing factor for Galantamine Hydrobromide peak should not be more 
than 2.0. Theoretical plates for Galantamine Hydrobromide peak should not be less 
than 2000. 
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Procedure: 
       20µl, five replicate injections of standard solution and two injections of sample 
solution are injected. The chromatograms are recorded and the peak response is 
measured. The assay is calculated by using following formula. 
            Ru     WS       5         100        50      P          100 
%Drug Content = -------x--------x------ x --------x------x-----x---------------- x100 
             Rs     100        50         WT      5      100     Label claim  
 
Where, 
Ru = Peak area of Galantamine Hydrobromide in sample solution 
Rs = Average peak area of Galantamine Hydrobromide in standard solution 
WS = Amount of Galantamine Hydrobromide taken in working standard (mg) 
WT = Amount of sample (mg) 
P = Potency of Galantamine Hydrobromide working standard used. 
 Moisture permeation test 
              The USP requires determination of the moisture permeation characteristics 
of single unit and unit dose containers to assure their suitability for packing 
capsules.  
                    The degree and rate of moisture penetration is determined by packing 
the dosage unit together with a color revealing desiccant pellet, exposing the 
packaged unit to known relative humidity over a specified time, observing the 
desiccant pellet for color change (indicating desiccating absorption of moisture) and 
comparing the pre and post weight of the packaged unit and also by the Karl Fisher 
Titration Equipme 
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                     VII. RESULTS AND DISCUSSIONS 
                 In the present study Nine formulations with variable coating polymers are 
used and the capsules are prepared and evaluated for physico-chemical, invitro 
dissolution studies. The formulated batches trails were shown in Table 6.9. 
7.1. Preformulation Studies 
                 Interparticulate interactions that influence the bulking properties of a 
powder with powder flow. A comparison of the bulk density and tapped density can 
give a measure of the relative importance of this interaction in a given powder; such 
a comparison is often used as an index of the ability of the powder to flow. The Bulk 
density and Tapped density was found to be 0.248 g/ml and 0.328 g/ml respectively.  
                A simple indication of ease with which a material can be induced to flow 
is given by application of a compressibility index. The value for Compressibility 
index of Galantamine Hydrobromide was found to be 24.39% that reflect the poor 
flow property of Galantamine Hydrobromide , which was supported by the Hausner 
ratio of 1.322.  
The physical characterization of the Polymer was done by evaluating them 
for the physical characteristics such as Bulk density, Tapped density, 
Compressibility index, and Hausner’s ratio and Angle of repose.  
a) Melting Point Determination: 
               Melting point of Galantamine Hydrobromide was found to be in the range 
269-270
o
c, which complied with Pharma Euro standards, indicating purity of the 
drug sample. 
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                                      Fig:7.1. DSC Of Galantamine Hydrobromide 
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b) Solubility: 
               Galantamine Hydrobromide was found to be slightly soluble in water, 
freely soluble in Sodium hydroxide Solution, Insoluble in Ether, Alcohol and 
Methylene chloride. 
c) Compatibility Study: 
      Compatibility studies were performed using FT-IR spectrophotometer. The FT-
IR spectrum of pure drug and physical mixture of drug and polymer were studied.  
 The peaks obtained in the spectra of each formulation correlates with the peaks of 
drug spectrum. This indicates that the drug was compatible with the formulation 
components. The Spectra for formulation is shown in below.  
 
Fig:7.2. FT-IR Spectrum of Optimized Product(F9). 
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Fig:7.3. FT-IR Spectrum of Placebo Pellets 
        
Fig:7.4. FT-R Spectrum of Pure Drug 
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d) Physical properties:  
                Physical properties of Galantamine Hydrobromide and polymers like Bulk 
density, Tapped density, Compressibility index and Hausner’s ratio and Angle of 
repose result is shown below table. 
 
Table:7.1. Physical properties of Galantamine hydrobromide 
Bulk density 
(gm/ml) 
Tapped Density 
(gm/ml) 
Compressibility 
Index 
Hausner’s 
Ratio 
Angle of 
repose 
0.248 0.328 24.39 % 1.322 26.04
0
 
 
 
e) Sieve analysis: 
             Table:7.2. Sieve analysis values of Galantamine Hydrobromide drug  
Sieve No Empty 
sieve(gm) 
Sample 
sieve(gm) 
Difference 
(gm) 
%Retained %Cumulative 
Retained 
#20 321.4 321.4 0 0 0 
#30 328.6 328.8 0.2 0.2 0.2 
#40 299.0 300.0 1.0 1.0 1.2 
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Weight of sample=100gm 
                 Through this sieve analysis we came to know that as large quantity of 
powder was retained on sieve No. 200, which indicates poor flow of the drug. Flow 
property and particle size are inversely proportional to each other as Galantamine 
Hydrobromide has fine grade of particles, it has poor flow. Hence the Galantamine 
Hydrobromide has poor flow property. 
7.2. Preparation of standard curve of Galantamine Hydrobromide 
 Preparation of P
H
 6.5 phosphate Buffer 
                  5.34g/l of Dibasic Sodium Phosphate Dihydrate in water. Adjust with 
phosphoric acid to 6.5P
H
 
Standard Curve of Galantamine Hydrobromide in P
H
 6.5 phosphate Buffer 
                  100 mg of Galantamine Hydrobromide was dissolved in 100 ml 
calibrated volumetric flask and completing to volume with P
H
 6.5 phosphate Buffer. 
From this 10ml pipette out in 100 ml calibrated volumetric flask and dilution was 
#60 287.2 297.4 10.2 10.2 11.4 
#80 245.0 268.2 23.2 23.2 34.6 
#100 274.0 299.0 25.0 25.0 59.6 
#200 270.0 310.0 40.0 40.0 99.6 
Receiver 348.8 349.0 0.2 0.2 99.8 
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made with P
H
 6.5phosphate Buffer. From this solution 2 ml, 4ml, 6ml, 8ml…up to 
10ml was pipette out in different 10 ml volumetric flask and this was finally diluted 
with P
H
 6.5phosphate Buffer to 10ml. The absorbance was noted max of 289nm. The 
absorbance values are shown in Table 7.3. 
                  Standard curve of Galantamine Hydrobromide was determined by 
plotting absorbance V/s concentration at 289 nm. and it follows the Beer’s law. The 
results were show in table no. and the R
2 
value is 0.9994 and slope is 0.0267. 
                   Table:7.3. Standard curve values of Galantamine Hydrobromide 
 
S.No Concentration µg/ml 
Absorbance  at 
289nm 
0 0 0.00 
1 2 0.06 
2 4 0.132 
3 6 0.212 
4 8 0.268 
5 10 0.327 
89 
 
 
Y=0.02673x+0.0007.                    R
2 
= 0.9994  
Fig:7.5.  Standard Curve of Galantamine Hydrobromide 
 
7.3. Determination of max of Galantamine Hydrobromide by UV spectrum 
 
Fig:7.6. UV Spectrum of Galantamine Hydrobromide 
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                     The max of Galantamine Hydrobromide is determined by UV spectrum 
the graph indicates that the maximum absorbance is observed at 289nm and it is the 
max of Galantamine Hydrobromide. 
Compatibility studies: 
                     The compatibility studies were carried out at 25
0
C/60% RH and   
40
0
C/75% RH for 0, 2 and 4 weeks. With respect to physical and chemical aspects, 
they were tested and there is no drug-excipients interactions are observed. 
                           Table:7.4. Compatibility study of Drug and Excipients 
S. No. Drug and Excipients Initial Physical Description 
25C / 60% RH 
and   40C / 75% RH 
(Closed) 
1st 
Week 
2nd 
Week 
4th 
Week 
1 Galantamine HBr White crystalline powder * * * 
2 
Galantamine HBr + Sugar 
spheres 
Off-white powder contain 
spherical pellets 
* * * 
3 
Galantamine HBr + Ethyl 
cellulose  N-45 
Off-white powder * * * 
4 Galantamine HBr +   white powder contain * * * 
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Poly ethylene glycol 6000 crystalline material 
5 
Galantamine HBr +   
HPMC  E5 
Off-white powder * * * 
6 
Galantamine HBr +   
Isopropyl alcohol 
Off-white thick mass * * * 
7 
Galantamine HBr +   
Purified Water 
Off-white thick mass. * * * 
8 
Galantamine HBr + Sugar 
spheres +    Ethyl cellulose 
N-45 + HPMC  + 
Polyethyleneglycol-6000+ 
Isopropylalcohol + Purified 
Water.    
Off-white powder containing 
lumps 
* * * 
  
Note: Star mark (*) indicates that there is no interaction between drug and 
excipients at 25 C/60% RH, 40C/75% RH. 
Trial batches formulae and their quantities as per W/W:350grams Batch 
Note: Drug is taken as overage to compensate the drug loss during drug layering     
process. 
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7.4. DISSOLUTION STUDIES 
F-1 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
                         Table:7.5. In-vitro dissolution profile of formulation F1 
 
Time (Hrs) 
Percentage of Drug release 
Razadyne ER F1 
0 0 0.00 
2 38.35 60.49 
6 67.72 87.88 
12 81.35 93.24 
16 90.09 98.65 
 
 
 
 
 
                      
                      Fig:7.7. Comparative dissolution profile of formulation F1 
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Observation: 
                     Based on the above results, the shape of the pellets is not uniform. 
During drug loading temperature was maintained below 22ºC. The pellets size and 
strength is good and release was more relatively. 
Conclusion 
                     The size and strength of the pellets are good and coating margin is 
around 17% is there for further development and to increase the HPMC ratio drug 
loading. 
F-2  Dissolution Profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
                            Table:7.6. Invitro dissolution profile of formulation F2 
 
Time (Hrs) 
Percentage of Drug release 
Razadyne ER F2 
0 0 0.00 
2 38.35 48.17 
6 67.72 82.12 
12 81.35 88.33 
16 90.09 89.04 
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Fig:7.8. Comparative dissolution profile of formulation F2 
Observation and Conclusion 
                     Based on the above results, Concentration of the Ethyl cellulose N45 
and HPMC to be increased to attain the desired drug release. 
F-3 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
                     Table:7.7. Invitro dissolution profile of formulation F3 
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Comparative Dissolution Profile 
 
Time (Hrs) 
Percentage of Drug release 
Razadyne ER F3 
0 0 0 
2 38.35 42.17 
6 67.72 72.12 
12 81.35 78.33 
16 90.09 89.04 
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                       Fig:7.9. Comparative dissolution profile of formulation F3 
Observation and Conclusion 
                          Based on the above results, Concentration of the Ethyl cellulose N45 
and  HPMC to be reduced to attain desired drug release. 
F-4 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
                     Table:7.8. Invitro dissolution profile of formulation F4 
 
Time 
(Hrs) 
Percentage of Drug release 
Razadyne 
ER 
F4 
0 0 0 
2 38.35 52.04 
6 67.72 68.12 
12 81.35 74.60 
16 90.09 80.62 
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                          Fig:7.10. Comparative dissolution profile of formulation F4 
 
Observation  
                       Based on the above results, the When we decreased the concentration 
of ethyl cellulose N45 and reducing the concentration of HPMC the changes in 
release in final and first hour. (Razadyne ER). 
 
Conclusion 
                        To overcome this problem we have planned to coat only with Ethyl 
cellulose N45 with decreasing HPMC level to get the more release in the final hour. 
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F-5 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
                          Table:7.9. Invitro dissolution profile of formulation F5 
                             
                    
 
 
 
 
 
                     
                     
 
 
 
     
       
       
       
       
       
       
       
       
       
       
                         
                       Fig :7.11. Comparative dissolution profile of formulation F5 
 
Time 
(Hrs) 
Percentage of Drug release 
Razadyne 
ER 
F4 
0 0 0 
2 38.35 61.01 
6 67.72 101.01 
12 81.35 100.68 
16 90.09 100.10 
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Observation 
                  Based on the above results, the concentration of Ethyl cellulose N45 to 
be increased to get the desired release. 
Conclusion 
                   To get the desired release we have to increase Ethyl cellulose N45 and 
the HPMC to be reduced to check the release changes in the starting point. 
 
F-6 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
Table:7.10. Invitro dissolution profile of formulation F6 
 
Time 
(Hrs) 
Percentage of Drug release 
Razadyne ER F6 
0 0 0 
2 38.35 28.61 
6 67.72 57.86 
12 81.35 74.58 
16 90.09 81.77 
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Fig:7.12.  Comparative dissolution profile of formulation F6 
 
Observation 
                    Based on the above results, the starting release in lower limit so the 
concentration of the HPMC is high so that has to reduce which retarteds release. 
 
Conclusion 
                    Because the sustained release polymer what we are coating as a second 
layer will give some of the effect on the 6.5 pH Acid media, by using the HPMC 
polymers as a Inner layer we can overcome. 
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F-7 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
 
Table:7.11. Invitro dissolution profile of formulation F7 
 
Time (Hrs)  
Percentage of Drug release 
Razadyne ER F7 
0 0 0 
2 38.35 52.39 
6 67.72 76.82 
12 81.35 82.06 
16 90.09 89.62 
 
 
 
    
      
      
      
      
      
      
      
      
      
      
                       Fig:7.13. Comparative dissolution profile of formulation F7 
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Observation  
                    Based on the above results, the ethyl cellulose N45 concentration to be 
increased. 
Conclusion 
                     To get the desired release we can increase the concentration of ethyl 
cellulose concentration. 
 
F-8 Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
Table:7.12. Invitro dissolution profile of formulation F8 
 
Time (Hrs) 
Percentage of Drug release 
Razadyne ER F8 
0 0 0 
2 38.35 42.28 
6 67.72 62.85 
12 81.35 79.34 
16 90.09 87.23 
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Fig:7.14. Comparative dissolution profile of formulation F8 
Observation  
                 Based on the above results, we have to increase ethyl cellulose 
concentration but the shape, size and strength of the pellets is good. 
 
Conclusion 
                 This formula is repeated from the core to confirm the formula. 
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F-9  Dissolution profile 
(Conditions: pH 6.5 phosphates buffer, 500 ml, 50 rpm and Apparatus II) 
 
                  Table:7.13. Invitro dissolution profile of formulation F9 
 
Time 
(Hrs) 
Percentage of Drug release 
Razadyne ER F9 
0 0 0 
2 38.35 38.25 
6 67.72 66.94 
12 81.35 80.97 
16 90.09 89.68 
    
 
 
 
 
 
Fig No.7.15. Comparative dissolution profile of formulation F9 
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Observation  
                Based on the above results, the release, shape, size and strength of the 
pellets is good and we got reproducible results. 
Conclusion 
               This formula is finalized for further optimization batch.  
 
Table:7.14 Invitro dissolution profile of formulations F1-F9 
S.No Time 
in 
hrs 
Percentage drug release 
Razadyne 
ER 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 0 0 0 0 0 0 0 0 0 0 0 
2 2 38.35 60.49 48.17 42.17 52.04 61.01 28.61 52.39 42.28 38.25 
3 6 67.72 87.88 82.12 72.12 68.12 101.01 57.86 76.82 62.85 66.94 
4 12 81.35 93.24 88.33 78.33 74.60 100.68 74.58 82.06 79.34 80.97 
5 16 90.09 98.65 89.04 89.04 80.62 100.10 81.77 89.62 87.23 89.68 
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Fig:7.16. Comparative dissolution profile of formulations F1-F9 
CHARACTERISTICS OF PELLETS FOR TRIAL F9 
 
Table:7.15. Charecterstics of pellets formulation F9 
Core pellets Results 
Yield (Limit-NLT 97%) 99.6% 
Bulk density 0.648 g/ml 
Tapped density  0.658 g/ml 
Compressibility index 1.519 
Angle of repose  26.04
0
 
Hausner’s ratio 1.015 
Time(In Hours) 
Comparative Dissolution profile 
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Sieve analysis for 100 gm 
for uncoated 
 
 # 16 passed 99 g 
 # 20  retained 99 g 
 #16 passed and 20 retained  99 g 
coated pellets  
Yield (Limit-NLT 96%) 99% 
Sieve analysis for 100 gm  
#16  passed 98 g 
#20  retained 98 g 
# 16 passed and 20 retained 98 g 
Bulk density 0.673 g/ml 
Tapped density  0.684 g/ml 
Compressibility index 1.70 
Angle of repose  27.46
0
 
Hausner’s ratio 1.01 
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Loading of coated pellets into capsules 
             The pellets after checking physical parameters this can be filled into 
capsules No.1 by using automatic capsule filling machine and the weight of capsule 
can be checked in filling of pellets into capsules.  
              The percentage weight variation of capsules is given as 5% to the 
total fill weight of capsule No.1 with sugar dummy pellets of same (#18-22 #) size. 
7.5. EVALUATION OF CAPSULES 
Weight variation 
                    The uniformity of dosage units may be demonstrated by 
determining weight variation or content uniformity. The weight variation 
method is as follows. 
  Hard gelatin capsules  
                      Table:7.16. Weight variation of all formulations of F1-F9 
Standard Deviation: 21.98932 
 
 
S.No Parameter F1 F2 F3 F4 F5 F6 F7       F8   F9 
1 Weight 
variation 
275.7 288.4 324.2 252.4 261.2 292.4 299.6 298.4 300.6 
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7.5.1 Content Uniformity: 
Assay by HPLC
 29 
 
Fig:7.17 HPLC Chromatogram of Blank 
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Fig:7.18 HPLC Chromatogram of Sample 
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Fig:7.19 HPLC Chromatogram of Standard 
 
The amount of active ingredient determined by assay is within the range of 
85% to 115% of the label claim for 9 of 10 dosage units assayed with no unit 
outside the range of 70% to 125% of label claim. Additional tests are prescribed 
when two or three dosage units are outside of the desired range but within the stated 
extremes and all the capsules are within the range of USP. 
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            Table:7.17. Content uniformity percentage of formulations F1-F9 
S.No F1 F2 F3 F4 F5 F6 F7 F8 F9 
Strength 
200mg 
109.9% 108.7% 105.0% 102.5% 104.2% 95.7% 100.6% 98.9% 99.0% 
                              Standard Deviation of Content Uniformity: 4.8075 
 
Disintegration test 
             Table:7.18. Disintegration values of all formulations F1-F9 
S.No Parameter F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Disintegration 
time in min. 
4.30 4.50 4.40 5.10 4.50 4.50 4.55 5.05 4.25 
                                 Standard Deviation Disintegration: 0.30219 
 
Moisture permeation test 
              The USP requires determination of the moisture permeation 
characteristics of single unit and unit dose containers to assure their suitability 
for packing capsules 
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              Table:7.19. Moisture content values of all formulations F1-F9 
Standard Deviation Moisture content: 0.6685 
7.6. STABILITY STUDIES 
Stability studies are to be carried out as per ICH guidelines for F9 batch of this 
product at long term, Intermediate and Accelerated storage conditions.                     
       Table:7.20. Evaluation parameter values at different temperature 
condi
tions        
 
 
 
 
 
  
 
S.No Parameter F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Moisture 
content  
3.2% 2.9% 3.2% 3.6% 3.3% 2.9% 2.3% 1.8% 1.75% 
S.No  Parameter Stability conditions at 
25°C 30°C 40°C 
1 Assay 100.13% 100.05% 100.10% 
2 Moisture content 1.72 % 1.75% 1.85 % 
3 Disintegration time 
in minutes 
4.30 4.25 4.20 
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Capsules Specification Parameters 
After filling of pellets into capsule, the parameters of capsules are observed. 
                              Table:7.21.Capsules specification parameters 
Parameters Results 
Strength 24mg 
Description Size ‘1’ hard gelatin capsules, with white transparent body and  
Bluecap containing white to off white spherical pellets of 18-
20# size. 
Capsule size 1 
Weight of 10 filled 
capsules (gm) 
3.007 gm 
Weight of 
individual capsules 
(mg) 
299.6, 298.4, 302.4, 299.6, 304.0, 298.6 299.6, 304.2, 302.0, 
299.4 
Locked length 
(mm) 
17.4, 17.6, 18.2, 17.8, 18.2, 17.5, 17.6, 17.4, 17.9, 18.1  
 
Standard deviation of Galantamine Extended Release Capsules: 2.267 
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                IIX SUMMARY AND CONCLUSION 
 The active pharmaceutical ingredient Galantamine Hydrobromide was 
subjected to preformulation study, which encompasses the “Accelerated drug 
excipient compatibility study” , and the results obtained with selected 
excipients showed good compatibility with Galantamine Hydrobromide 
drug.  
 Galantamine Hydrobromide coated pellets were formulated by using 
commercially available sugar pellets and Galantamine Hydrobromide  coated 
capsules were filled by Automatic capsule filling machine with various 
excipients. The optimization procedures aided in the stabilization of the 
formula and in the formulation of the Galantamine Hydrobromide Extended 
release capsules.  
 The Stability of the capsules and pellets  were determined by conducting 
“Accelerated stability testing” in 40°C ± 2°C / 75% ± 5%RH and 25ºC ± 2 
ºC/ 60%  ± 5% RH, and 30ºC±2ºC/65±5% RH conditions for 3 months as per 
ICH guidelines in HDPE containers. Finally after the duration, the product 
was analyzed for content uniformity, assay, disintegration and dissolution 
studies. By the stability studies, the formulated Galantamine Hydrobromide 
extended release capsules and pellets proved to be stable throughout the 
period of the storage. 
 The Galantamine Hydrobromide extended release pellets were loaded in size 
1 hard gelatin capsules. It showed good results in formulation of stable 
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dosage. The dissolution profile of the prepared Galantamine Hydrobromide 
extended release capsules were compared with that Reminyl extended 
release capsules (Razadyne ER) of the product. 
 The release was found nearer in the case of pellets loaded in capsules. And 
dissolution profile of Galantamine Hydrobromide extended release capsules 
were compared with that of innovator (Razadyne ER). The release was found 
similar to that of innovator. So the prepared product was said to be 
equivalent with innovator. 
 When coated pellets in capsule come to discussion of dosage form extended 
release showed better drug release. 
 Extended release pellets have minimum volume in size, greater surface area 
and    more surface activity. The area of the drug loaded pellets release rate 
was also more. And also there was no need of disintegration time for pellets 
in capsules. Because of Small size pellets enter into the systemic circulation 
in very fast.  Moreover there was no accumulation of drug in the body. Drug 
release rate was more when compared with the innovator (Razadyne ER) 
sample. 
 The release in the starting hours is controlled by increasing the concentration 
of Ethyl cellulose N-45 in the formulations in F9 formula and the HPMC is 
also increased. 
 Even though Galantamine Hydrobromide tablets and capsules, gels available 
in market the formulation of F9 was shows better results with innovator 
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product and the formulation process will be easy, safe and effective. 
 Finally I conclude that extended release pellets in capsule of formulation F9 
has relevant drug release rate rather than innovator and it has better stability, 
Bioavailability than the innovator. 
 
FUTURE SCOPE 
 In vivo evaluation of present study. 
 Development of extended release dosage form of Galantamine 
Hydrobromide by using Novel polymers. 
 Development of new method in the formulation process focusing on 
Alzheimer’s disease for effective Treatment. 
 
  
 
 
  
117 
 
                        IX. BIBILIOGRAPHY 
1. Lee TWY, Robinson JR., 20th ed, 2000. Remington: The Science and Practice 
of Pharmacy, Lippincott Williams and Wilkins, Maryland, 1069-70. 
2. Loyd V. Allen J, Nicholas G. Popovich, Howard C. Ansel, 8th ed, 2006. Ansel: 
Pharmaceutical dosage forms and drug delivery system, Lippincott Williams 
and Wilkins, Philadelphia, 260-275. 
3. Saptarshi D, Mukul S., Modified release dosage form and drug delivery. 
Journal of Pharm Research, 2009. 2(11):1728-29. 
4. Jain NK., Advances in controlled and Novel Drug Delivery, 2000. CBS 
publications, New Delhi. 268-269. 
5. Drug delivery, 1991. Available from: URL: www.wikipedia.org 
6. Robinson JR, Lee VH., 2nd ed, 1987. Controlled drug delivery: fundamentals 
& application, 36. Marcel Dekker, New York (NY). 
7. Chein YW., 2nd ed, 1992. Novel drug delivery systems, 2, 36, 140-141, 484. 
Marcel Dekker, Newyork (NY). 
8. Howard C. Ansel, Loyd V. Allen, Nicholas G. Popovich., 2000. Ansel’s 
Pharmaceutical Dosage forms and Drug Delivery Systems, 268. 
9. Schwartz BJ., Pharmaceutical Dosage Forms: Tablets. Marcel Dekker, New 
York. (2000). 75-130. 
10. Aulton M.E, international student Edition, 2001. Pharmaceutics-The Science 
of      Dosage form design, 129-191. Churchill Livingston. 
118 
 
11. Leon Lachman, Joseph L, Kanig., 3rd ed, 1986.  The theory and practice of                                                                                 
industrial pharmacy, 331-2, 364-8. Lea & Febiger, Philadelphia. 
12. Peter ridgeway watt, N Anthony Armstrong, “Tablet and Capsule Machine 
Instrumentation”, Pharmaceutical Press. Chicago. 
13. Shalin A. Modi, P. D. Gaikwad, V. H. Bankar, S. P. Pawar, “Sustained release 
drug delivery system: a review” International Journal of Pharma Research and 
Development 2011; 11: 147-198. 
14. Fei Wu, Tuo Jin, “Polymer-Based Sustained-Release Dosage Forms for 
Protein Drugs, Challenges and Recent Advances” AAPS PharmSciTech, 
December 2008: AAPS PharmSciTech, Vol. 9, No. 4, December 2008, 1218-
1226. 
15. William Andrew, 3rd ed. Pharmaceutical Manufacturing Encyclopedia, 
Volume 1. 
16. Wise, Donald L., 2000. Handbook of Pharmaceutical Controlled Release 
Technology, 473. 
17. James Swarbick, Encyclopedia of Pharmaceutical Technology, vol:3, 1993; 
2652-2663. 
18. K. Roth, Hoff, Pharma Bead Coating, April 17, 2008. 
19. Olsen K, Ghebre-Sellassie I., 1sted, 1989.Pharmaceutical Pelletization 
Technology, 39-69. Marcel and Dekker, New York. 
119 
 
20. Raymond C, Rowe, Paul JS, Paul JW, 4th ed., 2003. Hand Book of 
Pharmaceutical Excipients, 345, 1294, 1998. 
21. http://en.wikipedia.org/wiki/Alzheimer%27s_disease 
22. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, et al. High-
dose      B vitamin supplementation and cognitive decline in Alzheimer's 
disease: a randomized controlled trial. JAMA. 2008; 300:1774-1783. 
23. Wald mar G. Recommendations for the diagnosis and management of 
Alzheimer's disease and other disorders associated with dementia: EFNS 
guideline. European journal 2007; 14(1): 1–26. 
24. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qua
lity/Q1A_R2/Step4/Q1A_R2__Guideline.pdf 
25. http://www.drugs.com/pro/galantamine 
26. The United States Pharmacopeia. Twenty-third revision. United States 
Pharmacopeial Convention Inc., Rockville, MD, 1995. 
27. Paul W C, Scatina J, Samuel F and Sisenwine (1995), Journal of Liquid 
Chromatography and Related Technologies, 18: 9. p 1801 – 1808 
28. Timo Erkinjuntti, “Treatment options: The latest evidence with galantamine 
(ReminylR)”, Elsevier-Journal of the Neurological Sciences 203– 204 (2002) 
125–130 
120 
 
29. Patrick Vigneault, Sarah Bourgault. et al.,” Galantamine (Reminyl®) delays 
cardiac ventricular repolarization and prolongs the QT interval by blocking the 
HERG current”, European Journal of Pharmacology 681 (2012) 68–74 
30. Alexis Kays Leonard. et al., “Development of a novel high-concentration 
Galantamine formulation suitable for intranasal delivery” Journal of 
Pharmaceutical Sciences, Volume 94, Issue 8, August 2005, pages 1736–1746 
31. Khatavkar UN, et al., “Development and in vivo evaluation of novel 
monolithic controlled release compositions of Galantamine Hydrobromide as 
against reservoir technology”, Pharmaceutical Development Technology, Jul 
20, 2011 [PubMed]. 
32. Sunil Vandse, Controlled release Galantamine Formulations, United States 
Patent No: 7955622, Issued on June 7, 2011. 
33. Ben Seltzer, “Galantamine-ER for the treatment of mild-to-moderate 
Alzheimer’s disease”, February 2, 2010. [PubMed]. 
34. Olin J, Schneider L, Galantamine for Alzheimer's disease, 2001(4), [PubMed]. 
35. Guk-Hee Suh, et al., A prospective, Double-blind Controlled Comparision of 
three doses of Galantamine in a Korean population, Clinical Therapeutics Vol 
26. Nov 19, 2004. 
36. Hugo Geerts, et al., Indicators of Neuroprotection with Galantamine. Brain 
Research Bulletin 64 (2005) 519–524. 
121 
 
37. Tang, et al., Galantamine Formulations, United States Patent No: 0142193 A1, 
Issued on Jun 30, 2005. 
 
